() -Several pharmaceutical companies have said they will sell drugs direct to patients in the U. and offered discounts ...

Cantor Fitzgerald analyst Li Watsek raised the firm’s price target on Ascendis Pharma (ASND) to $254 from $203 and keeps an Overweight rating on ...

When patients are prescribed complex therapies — like specialty drugs, cell and gene treatments, or high-cost biologics — the path to treatment is rarely straightforward. Filling a prescription can ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N (NYSE: MODN), the leader in revenue optimization and compliance today announced new product innovations geared towards the increasingly complex regulatory ...

As the pharmaceutical sector grows in India, Jamkas Pharmaceuticals emerges as a reliable third-party manufacturer.

Pharmaceutical companies are just beginning to think of digital health offerings as therapeutics, Dr. Joseph Kvedar, the vice president of Connected Health at Partners HealthCare, told MobiHealthNews ...

NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule ...

Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).

Donald Trump announced 100% tariffs on imported branded or patented pharmaceutical products from October 1, 2025, unless companies build US manufacturing facilities. This policy primarily impacts ...

Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio ...

Model N has made further enhancements to 340B Vigilance, one of the company’s key products for pharma manufacturers to manage 340B rebates and compliance. New 340B Vigilance enhancements simplify ...

Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered discounts ...